Green Cross Corp
KRX:006280
Green Cross Corp
EPS (Diluted)
Green Cross Corp
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Green Cross Corp
KRX:006280
|
EPS (Diluted)
-₩2.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
EPS (Diluted)
₩2k
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
9%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
EPS (Diluted)
₩11.9k
|
CAGR 3-Years
39%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
EPS (Diluted)
₩8.9k
|
CAGR 3-Years
24%
|
CAGR 5-Years
37%
|
CAGR 10-Years
22%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
EPS (Diluted)
₩1.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
44%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
EPS (Diluted)
-₩1.2k
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Green Cross Corp
Glance View
Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.
See Also
What is Green Cross Corp's EPS (Diluted)?
EPS (Diluted)
-2.3k
KRW
Based on the financial report for Dec 31, 2024, Green Cross Corp's EPS (Diluted) amounts to -2.3k KRW.
What is Green Cross Corp's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-47%
Over the last year, the EPS (Diluted) growth was 1%.
You don't have any saved screeners yet